EN DE
Watch Dicot AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Dicot AB (DICOT) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Dicot AB stock SEK 0.16, price SEK 0.21, that is 25.8% below the price, quality 44 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE

DA Dicot AB logo Thin data Nov 10, 2026

Dicot AB

DICOT · ST
Expensive, weak quality

Our calculation puts a fair price 26% below what the stock costs today.

Quality 44/100
Fair value kr 0.1569 · Overvalued
Negative free cash flow
Trails peers (1/7)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Dicot AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 1.08 kr 0.1050 Fair Value kr 0.1569 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.1050 – kr 1.08 · fair‑value band kr 0.1177 – kr 0.1962 · the kr 0.2114 price screens above the kr 0.1569 fair value. As of Nov 10, 2026.

Follow Dicot in your weekly email

Every Wednesday you see whether Dicot is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation.

Show moreShow less

The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.

Stock analysis

Dicot AB (DICOT) currently trades at kr 0.2114, while our estimate is kr 0.1569, 26% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.1177 (bear) to kr 0.1962 (bull), the price of kr 0.2114 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Dicot AB reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −80.2M SEK in FY2025.

Key figures

Market cap 733M SEK (≈ $74.3M) Micro · EPS (TTM) kr −0.0400 · Return on equity −47.0% · Return on assets (EBIT) −114% (5-year average) · Free cash flow −85.9M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 56% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −26%, DICOT screens cheaper than that median.

Fair Value

Bear kr 0.1177 Fair Value kr 0.1569 Bull kr 0.1962
Price kr 0.2114 · Downside -25.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 69
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 38
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DICOT screens overvalued: fair value 26% below the price. Compare with Merck KGaA →

Compare Dicot AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −25.8% · Below median
Profitability
Return on assets −93.9% · Bottom 25%
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.01× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs DICOT
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs DICOT
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs DICOT
Haleon plc HLN $9.06 $8.62 −5% vs DICOT
Merck KGaA MRK €149.35 €109.18 −27% vs DICOT
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs DICOT
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs DICOT
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs DICOT
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs DICOT
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs DICOT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dicot AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Dicot AB Fair Value". https://www.fairvalue-calculator.com/stock/DICOT

Frequently asked questions

Is Dicot AB (DICOT) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.1569 versus a price of kr 0.2114, about 26% lower (overvalued).
What is the fair value of DICOT?
Our estimate for Dicot AB is kr 0.1569 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.2114.
What is the quality score of DICOT?
Dicot AB has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dicot AB (DICOT)?
Our calculated price target is the estimate of kr 0.1569 (as of Nov 10, 2026). Cautious scenario kr 0.1177, optimistic scenario kr 0.1962. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Dicot AB stock forecast for 2026?
Our estimate puts fair value at kr 0.1569, about 26% lower versus a price of kr 0.2114 (overvalued). Cautious scenario kr 0.1177, optimistic scenario kr 0.1962. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Dicot AB (DICOT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dicot AB it is kr 0.1569 per share (as of Nov 10, 2026), against a price of kr 0.2114.
Is Dicot AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, DICOT trades above its calculated fair value: price kr 0.2114, fair value kr 0.1569, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DICOT?
No. The price is what the market pays today (kr 0.2114); the fair value is what the company's own numbers justify (kr 0.1569). For Dicot AB the two are kr 0.0545 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dicot AB worth?
The market values Dicot AB at about 733M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.2114; our models calculate a fair value of kr 0.1569 per share.
What do the bullish and bearish scenarios say about DICOT?
Our models span a range for Dicot AB: cautious scenario kr 0.1177, base kr 0.1569, optimistic kr 0.1962 per share (as of Nov 10, 2026, price kr 0.2114). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dicot AB (DICOT)?
Balance-sheet figures for Dicot AB (as of Nov 10, 2026): return on equity −47.0%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is DICOT from its 52-week high?
Dicot AB trades at kr 0.2114, about 56% below its 52-week high of kr 0.4855 and 18% above the low of kr 0.1796 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1569 is for.
Which stocks are comparable to Dicot AB?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dicot AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.2114, calculated fair value kr 0.1569 (−26%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Dicot AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dicot AB (DICOT)?
The closing price on Nov 6, 2026 was kr 0.2114. Our estimate is kr 0.1569, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dicot AB right now?
The price sits above even our optimistic bull case (kr 0.1962). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Dicot AB

How large is the market capitalisation of Dicot AB (DICOT)?
The market capitalisation of Dicot AB is 733M SEK (≈ $74.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Dicot AB (DICOT)?
Earnings per share at Dicot AB are kr −0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Dicot AB (DICOT)?
The return on equity (ROE) of Dicot AB is −47.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dicot AB (DICOT)?
On an EBIT basis the return on assets of Dicot AB is −114% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Dicot AB (DICOT) generate?
The free cash flow of Dicot AB is −85.9M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Dicot AB in the live analysis

One click puts Dicot AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.